Summary
Global Markets Direct’s, ‘Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2016’, provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Secondary Progressive Multiple Sclerosis (SPMS)
- The report reviews pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Secondary Progressive Multiple Sclerosis (SPMS) therapeutics and enlists all their major and minor projects
- The report assesses Secondary Progressive Multiple Sclerosis (SPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AB Science SA
Actelion Ltd
Biogen, Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Glialogix, Inc.
Immune Response BioPharma, Inc.
Innate Immunotherapeutics Ltd
Kyorin Pharmaceutical Co., Ltd.
Mallinckrodt Plc
MedDay SA
MedImmune, LLC
Merck KGaA
Meta-I
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Secondary Progressive Multiple Sclerosis (SPMS) Overview 9
Therapeutics Development 10
Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) - Overview 10
Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics under Development by Companies 11
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Secondary Progressive Multiple Sclerosis (SPMS) - Products under Development by Companies 16
Secondary Progressive Multiple Sclerosis (SPMS) - Companies Involved in Therapeutics Development 17
AB Science SA 17
Actelion Ltd 18
Biogen, Inc. 19
F. Hoffmann-La Roche Ltd. 20
Genzyme Corporation 21
Glialogix, Inc. 22
Immune Response BioPharma, Inc. 23
Innate Immunotherapeutics Ltd 24
Kyorin Pharmaceutical Co., Ltd. 25
Mallinckrodt Plc 26
MedDay SA 27
MedImmune, LLC 28
Merck KGaA 29
Meta-IQ ApS 30
Novartis AG 31
Opexa Therapeutics, Inc. 32
Xenetic Biosciences (UK) Limited 33
Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 38
7Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
biotin - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
DC-TAB - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
etomoxir - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
GLX-1112 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
GZ-402668 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
IB-MS - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ibudilast - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
imilecleucel-T - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
inebilizumab - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
interferon beta-1b - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
IR-902 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
M-2736 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
masitinib - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
methoxsalen - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
MIS-416 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
ocrelizumab - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
opicinumab - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
OSX-110 - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
ponesimod - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
siponimod - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
Xemys - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
Secondary Progressive Multiple Sclerosis (SPMS) - Dormant Projects 108
Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products 109
Secondary Progressive Multiple Sclerosis (SPMS) - Product Development Milestones 110
Featured News & Press Releases 110
May 25, 2016: MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial 110
Apr 21, 2016: MedDay reports full data from pivotal Phase IIb/III MS-SPI / MS-ON studies with MD1003 in Multiple Sclerosis at AAN 110
Apr 13, 2016: Innate Immunotherapeutics announces clinical trial fully enrolled and receives strong interest from potential Pharma partners 112
Apr 01, 2016: PJSC Pharmsynthez Completes Follow Up and Data Analysis From a Phase 2 Study of Novel Therapeutic Vaccine Xemys for Multiple Sclerosis 113
Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis 114
Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003 114
Oct 07, 2015: MedDay reports additional positive analyses of its pivotal study with MD1003 in patients with primary and secondary Progressive Multiple Sclerosis 116
Oct 06, 2015: Opexa Announces Granting of New T-cell Patents Covering Tcelna; Patent Estate Increases to 160 Issued Patents 117
Aug 06, 2015: Medical Need Europe appoints Durbin as latest distribution partner 117
Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 118
Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC 118
Oct 07, 2014: Update on Innate’s Phase 2B trial and other recent activities 119
Aug 19, 2014: Innate’s Phase 2B clinical trial on SPMS to start recruiting patients following Perth site obtaining ethics approval 119
Jun 20, 2014: Update on Phase 2B Trial of MIS416 in Patients with Secondary Progressive Multiple Sclerosis 120
Jun 18, 2014: Compassionate Use Programme Update 121
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 122
Disclaimer 123
List of Tables
Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2016 10
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by AB Science SA, H2 2016 17
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Actelion Ltd, H2 2016 18
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Biogen, Inc., H2 2016 19
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 20
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Genzyme Corporation, H2 2016 21
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Glialogix, Inc., H2 2016 22
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Immune Response BioPharma, Inc., H2 2016 23
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Innate Immunotherapeutics Ltd, H2 2016 24
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 25
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Mallinckrodt Plc, H2 2016 26
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by MedDay SA, H2 2016 27
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by MedImmune, LLC, H2 2016 28
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Merck KGaA, H2 2016 29
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Meta-IQ ApS, H2 2016 30
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Novartis AG, H2 2016 31
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Opexa Therapeutics, Inc., H2 2016 32
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016 33
Assessment by Monotherapy Products, H2 2016 34
Number of Products by Stage and Target, H2 2016 36
Number of Products by Stage and Mechanism of Action, H2 2016 39
Number of Products by Stage and Route of Administration, H2 2016 42
Number of Products by Stage and Molecule Type, H2 2016 44
Secondary Progressive Multiple Sclerosis (SPMS) - Dormant Projects, H2 2016 108
Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products, H2 2016 109
List of Figures
Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 14
Assessment by Monotherapy Products, H2 2016 34
Number of Products by Top 10 Targets, H2 2016 35
Number of Products by Stage and Top 10 Targets, H2 2016 35
Number of Products by Top 10 Mechanism of Actions, H2 2016 38
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 38
Number of Products by Routes of Administration, H2 2016 41
Number of Products by Stage and Routes of Administration, H2 2016 41
Number of Products by Molecule Types, H2 2016 43
Number of Products by Stage and Molecule Types, H2 2016 43
